Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surgery plus Sorafenib vs Sorafenib in HCC with Portal Vein Invasion
NCT03971201Phase 2Unknown
- Sponsor
- White Plains Hospital
- Start
- Sep 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by White Plains Hospital. Status: unknown.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03971201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971201.